The Impact of Sildenafil on Molecular Science and Sexual Health

Krane, 2001, Changes in ED therapy in the Viagra era, World J. Urol., 19, 23, 10.1007/s003450000172 Burnett, 2002, Nitric oxide regulation of penile erection: biology and therapeutic implications, J. Androl., 23, S20 Kim, 1991, A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle, J. Clin. Invest, 88, 112, 10.1172/JCI115266 Rajfer, 1992, Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission, N. Engl. J. Med., 326, 90, 10.1056/NEJM199201093260203 Burnett, 1992, Nitric oxide: a physiologic mediator of penile erection, Science, 257, 401, 10.1126/science.1378650 Taher, 1997, Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle, World J. Urol., 15, 32, 10.1007/BF01275154 Wallis, 1999, Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro, Am. J. Cardiol., 83, 3C, 10.1016/S0002-9149(99)00042-9 Maytom MC, Osterloh IH, Wicker PA. Development of an oral drug to treat male erectile dysfunction: from the chemist’s bench to the drug store. In: Morales A, editor. Erectile dysfunction issues in current pharmacotherapy. London: Martin Duntz Ltd.; 1998. p. 189–207. Campbell, 2000, Science, art and drug discovery: a personal perspective, Clin. Sci. (Lond), 99, 255, 10.1042/CS20000140 Stief, 1998, The effect of the specific phosphodiesterase (PDE) inhibitors on human and rabbit cavernous tissue in vitro and in vivo, J. Urol., 159, 1390, 10.1016/S0022-5347(01)63622-X Trigo-Rocha, 1994, Intracellular mechanism of penile erection in monkeys, Neurourol. Urodyn., 13, 71, 10.1002/nau.1930130110 Christ, 1997, Integrative erectile biology: the role of signal transduction and cell-to-cell communication in coordinating corporal smooth muscle tone and penile erection, Int. J. Impot. Res., 9, 69, 10.1038/sj.ijir.3900277 Rosen, 2002, The International Index of Erectile Function (IIEF): a state-of-the-art science review, Int. J. Impot. Res., 14, 226, 10.1038/sj.ijir.3900857 Althof, 1999, EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction, Urology, 53, 793, 10.1016/S0090-4295(98)00582-2 Feldman, 1994, Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study, J. Urol., 151, 54, 10.1016/S0022-5347(17)34871-1 Guay, 2001, Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors, J. Androl., 22, 793 Steers, 2003, Viability and safety of combination drug therapies for erectile dysfunction, J. Urol., 170, S20, 10.1097/01.ju.0000075120.89700.9b Jardin A, Wagner G, Khoury S, Giuliano F, Goldstein I, Padma-Nathan H, et al., Recommendations of the 1st International Consultation on Erectile Dysfunction. In: Jardin A, Wagner G, Khoury S, Giuliano, Padma-Nathan H, Rosen R, editors. Erectile Dysfunction. Plymouth: Health Publication Ltd.; 2000. p. 711–26. Morales, 1995, Oral and topical treatment of erectile dysfunction. Present and future, Urol. Clin. North Am., 22, 879, 10.1016/S0094-0143(21)00701-1